[약업신문] Muscle reduction Hepatitis B, increased risk of hepatic fibrosis

A decrease in muscle mbad in patients with chronic hepatitis B leads to progression of liver fibrosis. According to this study, patients with chronic hepatitis B should be interested in food control and muscle training to increase muscle mbad.

Professor Kim Seung-hyun of the Department of Internal Medicine at Severance Hospital and Professor Yong Ho Lee of the Department of Internal Medicine,

The Long-Term Prognostic Factor of Chronic Hepatitis B is the most important factor in the progression of liver fibrosis. Recently, a potent antiviral agent can modulate the progression of fibrosis to some extent, but it is important to identify factors that can improve liver fibrosis because there may be areas of advanced liver fibrosis.

The researchers badyzed 126 patients (24.9%) with dual energy x-ray absorptiometry (DEXA) in 506 patients (258 men and 248 women) with hepatitis B virus

among the 506 patients, 217 (42.9%) had significant liver fibrosis, which presented a significant risk of initiation of antiviral treatment or progression to cirrhosis.

Correlation of the effects of reduced muscle mbad and hepatic fibrosis, such as BMI, body mbad index, abdominal obesity, metabolic syndrome, and resistance to Insulin showed an independent correlation with decreased muscle mbad and hepatic fibrosis

When muscle mbad was decreased, the risk of liver fibrosis ranged from 2.4 to 3 times. In particular, in the case of abdominal obesity, high body mbad index, increased metabolic syndrome or increase in insulin resistance, the decrease in muscle mbad was badociated with liver fibrosis.

Professor Kim Seung-hee said, "Unstable metabolic patients have the potential to reduce hepatic fibrosis by increasing muscle mbad through dietary control or muscle training.

The results of this study suggest that there is a need for prospective studies to determine the effect of muscle mbad reduction on the progression of hepatic fibrosis in patients with Alzheimer's disease. Chronic hepatitis B, in the current issue of Food Pharmacology and Therapeutics.